Donald M. O'Rourke

Professor

University of Pennsylvania
Country flagUnited States

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Articles (5)

Purpose: Noninvasive prognostic biomarkers to inform clinical decision-making are an urgent unmet need for the management of patients with glioblastoma (GBM). We previously showed that higher circulating cell-free DNA (ccfDNA) concentration is associated with worse survival in GBM. However, the biology underlying this is unknown. Experimental Design: We prospectively enrolled 129 patients with treatment-naïve GBM with blood drawn prior to initial resection (baseline) and at the time of the first postradiotherapy MRI. We performed ccfDNA methylation deconvolution to determine cellular sources of ccfDNA. ELISA was performed to detect citrullinated histone 3 (citH3), a marker of neutrophil extracellular traps (NET). Multiplex proteomic analysis was used to measure soluble inflammatory proteins. Results: We found that neutrophils contributed the highest proportion of prognostic ccfDNA. The percentage of ccfDNA derived from neutrophils was correlated with total [ccfDNA] but only in patients receiving preoperative corticosteroids. At baseline and on therapy, [citH3] was significantly higher in the plasma of patients with GBM receiving corticosteroids compared with corticosteroid-naïve GBM or no-cancer controls. Unsupervised hierarchical clustering of ccfDNA methylation patterns yielded two clusters, with one enriched for patients with the NETosis phenotype and who received corticosteroids. Unsupervised clustering of circulating inflammatory proteins yielded similar results. Conclusions: These data suggest neutrophil-mediated NETosis is the dominant source of prognostic ccfDNA in patients with GBM and may be associated with glucocorticoid exposure. If further studies show that pharmacological inhibition of NETosis can mitigate the deleterious effects of corticosteroids, these plasma markers will have important clinical utility as noninvasive correlative biomarkers.

Year:

2025

Supplemental Figure 1. Patients and assays Supplemental Figure 2. Survival analysis at baseline and post-radiation Supplemental Figure 3. Correlative analysis of all ccfDNA deconvolution subsets with [ccfDNA]. Supplemental Figure 4. Analysis of % neutrophil tissue DNA and pre-operative steroids. Supplemental Figure 5. Correlative analysis of all ccfDNA deconvolution subsets with [citH3]. Supplemental Figure 6. Analysis of % neutrophil tissue DNA and [citH3]. Supplemental Figure 7. Analysis of [citH3], pre-operative steroid dose, and tumor volume. Supplemental Figure 8. Analysis of % neutrophil ccfDNA by steroid exposure. Supplemental Figure 9. Percent neutrophil ccfDNA and [citH3] at time of first post-radiation MRI. Supplemental Figure 10. Analysis of % neutrophil ccfDNA and total [ccfDNA] by steroid exposure. Supplemental Figure 11. Molecular sub-type analysis of Clusters 1 and 2 from plasma ccfDNA differential methylation results. Supplemental Figure 12. Unsupervised clustering of tissue DNA methylation data, differential methylation, and pathway analysis. Supplemental Figure 13. Analysis of Clusters 1 and 2 from tissue DNA differential methylation analysis. Supplemental Figure 14. Analysis of Clusters 1 and 2 from plasma ccfDNA differential methylation results.

Year:

2025

List of all methylGSA results for (Gene Ontology,GO, gene sets) with differential methylation comparing patients in cluster 1 vs cluster 2 from unsupervised clustering of the tissue DNA methylation results.

Year:

2025

Patients diagnosed with glioblastoma (GBM) receive a devastating prognosis of less than 15 months, and recurrence of GBM is most often local, suggesting that regional therapies would serve both immediate and long-term needs of patients. Here, we investigate a biomaterials-based approach for local delivery of chimeric antigen receptor (CAR) T cells using a murine model of partial GBM resection that mimics patient recurrence. We demonstrate that hydrogel delivery of CAR T cells directly into the intracranial resection cavity can stably implant cellular immunotherapies against CNS solid tumors, and significantly prolongs survival in recurrent GBM-bearing mice compared to those receiving resection alone. One Sentence Summary During resection surgeries for brain tumors, delivering cell therapy at time of surgery could improve outcomes for patients.

Year:

2025

Over the past two decades, there have been advances in surgical technologies and chemoradiation strategies for glioblastoma, yet durable remissions are rarely seen. As the biological challenges and genetic basis of glioblastoma have become more understood, new therapeutic strategies may lead to more durable clinical responses and long-term remissions. We believe specialized academic centers that form meaningful corporate partnerships to complement basic science infrastructure and use adaptive clinical trial designs will achieve more rapid translation of innovative approaches to glioblastoma. Here we outline the core biological challenges to be overcome in the management of glioblastoma.

Year:

2022

Collaborators (9)

Richard E. Phillips

University of Pennsylvania

UNITED STATES
View details

Ali Nabavizadeh

University of Pennsylvania

UNITED STATES
View details

Erica L. Carpenter

University of Pennsylvania

UNITED STATES
View details

Matija Snuderl

Assistant Professor (Clinical) of Pathology

NYU School of Medicine

UNITED STATES
View details

Wanding Zhou

Assistant Professor

Children's Hospital of Philadelphia

UNITED STATES
View details

Nicholas Seewald

Assistant Professor

University of Pennsylvania

UNITED STATES
View details

Zev Binder

Research Assistant Professor

University of Pennsylvania

UNITED STATES
View details

Kandace Gollomp

Assistant Professor

Children's Hospital of Philadelphia

UNITED STATES
View details

Stephen J Bagley

University of Pennsylvania

UNITED STATES
View details